Andrea Leonardi

List of Publications by Year
in descending order

124	5,466	71004	111975
papers	citations	43 h-index	67 g-index

132	132	132	3008
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers. Ocular Immunology and Inflammation, 2023, 31, 1707-1715.	1.0	0
2	Antiviral response in vernal keratoconjunctivitis may be protective against COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 298-300.	2.7	2
3	Epithelial barrier dysfunction in ocular allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1360-1372.	2.7	28
4	Tracing the SARS-CoV-2 infection on the ocular surface: Overview and preliminary corneoscleral transcriptome sequencing. Experimental Eye Research, 2022, 217, 108975.	1.2	2
5	Treatment of Ligneous Conjunctivitis with Plasminogen Eyedrops. Ophthalmology, 2022, 129, 955-957.	2.5	5
6	Ocular allergy in children and adolescents. Allergologia Et Immunopathologia, 2022, 50, 30-36.	1.0	4
7	Corneal Microstructural Changes by Confocal Microscopy in Vernal Keratoconjunctivitis Patients Treated with Topical Cyclosporine. Ocular Immunology and Inflammation, 2021, 29, 1599-1605.	1.0	3
8	Conjunctival transcriptome analysis reveals the overexpression of multiple pattern recognition receptors in vernal keratoconjunctivitis. Ocular Surface, 2021, 19, 241-248.	2.2	20
9	Allergy and Dry Eye Disease. Ocular Immunology and Inflammation, 2021, 29, 1168-1176.	1.0	30
10	Tear Nâ€glycomics in vernal and atopic keratoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2500-2509.	2.7	10
11	Metagenomic analysis of the conjunctival bacterial and fungal microbiome in vernal keratoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3215-3217.	2.7	8
12	The effects of the COVID-19 pandemic on the treatment of allergic eye diseases. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 500-506.	1.1	1
13	Detection of severe acute respiratory syndrome coronavirus 2 in corneas from asymptomatic donors. Acta Ophthalmologica, 2021, 99, e1245-e1246.	0.6	7
14	Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy. British Journal of Ophthalmology, 2020, 104, 718-722.	2.1	10
15	Twelve-Month Results of Cyclosporine A Cationic Emulsion in a Randomized Study in Patients With Pediatric Vernal Keratoconjunctivitis. American Journal of Ophthalmology, 2020, 212, 116-126.	1.7	30
16	ICON. Annals of Allergy, Asthma and Immunology, 2020, 124, 118-134.	0.5	79
17	Managing ocular allergy in the time of COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2399-2402.	2.7	7
18	Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 355-365.	0.6	19

#	Article	IF	Citations
19	Ocular Surface Expression of SARS-CoV-2 Receptors. Ocular Immunology and Inflammation, 2020, 28, 735-738.	1.0	69
20	Clinical efficacy assessment in severe vernal keratoconjunctivitis: preliminary validation of a new penalties-adjusted corneal fluorescein staining score. Journal of Market Access & Health Policy, 2020, 8, 1748492.	0.8	2
21	The regulatory activity of autophagy in conjunctival fibroblasts and its possible role in vernal keratoconjunctivitis. Journal of Allergy and Clinical Immunology, 2020, 146, 1210-1213.e9.	1.5	25
22	Plasminogen Eye Drops Are Effective in Preventing Recurrence of Pseudomembranes in Ligneous Conjunctivitis: Results from the Phase 2/3 KB046 Trial. Blood, 2020, 136, 24-25.	0.6	0
23	A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis. Ophthalmology, 2019, 126, 671-681.	2.5	60
24	Management of ocular allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1611-1630.	2.7	62
25	Office-based ocular procedures for the allergist. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 488-494.	1.1	5
26	Efficacy and Tolerability of Ketotifen in the Treatment Of Seasonal Allergic Conjunctivitis: Comparison between Ketotifen 0.025% and 0.05% Eye Drops. Ocular Immunology and Inflammation, 2019, 27, 1352-1356.	1.0	11
27	Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. British Journal of Ophthalmology, 2019, 103, 125-131.	2.1	35
28	Corneal staining patterns in vernal keratoconjunctivitis: the new VKC-CLEK scoring scale. British Journal of Ophthalmology, 2018, 102, 1448-1453.	2.1	20
29	Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study. Clinical Therapeutics, 2018, 40, 1894-1906.	1.1	13
30	Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis. Ophthalmology, 2018, 125, 1984-1993.	2.5	27
31	Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy. Global & Regional Health Technology Assessment, 2018, 2018, 228424031877715.	0.2	1
32	Neutrophils cause obstruction of eyelid sebaceous glands in inflammatory eye disease in mice. Science Translational Medicine, 2018, 10, .	5.8	42
33	Keratitis in Dry Eye Disease and Topical Ciclosporin A. Ocular Immunology and Inflammation, 2017, 25, 577-586.	1.0	18
34	Does Ocular Neuropathic Pain Deserve an Autonomous Position in the IHS Classification? Clinical and Diagnostic Evidences. Headache, 2017, 57, 962-963.	1.8	1
35	Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. European Respiratory Journal, 2017, 49, 1602006.	3.1	63
36	Pan-European survey of the topical ocular use of cyclosporine A. Journal Francais D'Ophtalmologie, 2017, 40, 187-195.	0.2	18

#	Article	IF	Citations
37	Diagnostic tools in ocular allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1485-1498.	2.7	45
38	A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye. European Journal of Ophthalmology, 2017, 27, 520-530.	0.7	65
39	Conjunctival allergen provocation test : guidelines for daily practice. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 43-54.	2.7	81
40	One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease. European Journal of Ophthalmology, 2017, 27, 678-685.	0.7	55
41	Author's Reply to: â€œConcerns Over: Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Diseaseâ€. European Journal of Ophthalmology, 2017, 27, e194-e195.	0.7	2
42	Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial. European Journal of Ophthalmology, 2016, 26, 287-296.	0.7	137
43	Chaperone patterns in vernal keratoconjunctivitis are distinctive of cell and Hsp type and are modified by inflammatory stimuli. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 403-411.	2.7	8
44	Microarrayâ€based IgE detection in tears of patients with vernal keratoconjunctivitis. Pediatric Allergy and Immunology, 2015, 26, 641-645.	1.1	28
45	Allergic conjunctivitis: a crossâ€sectional study. Clinical and Experimental Allergy, 2015, 45, 1118-1125.	1.4	43
46	Epidemiology of allergic conjunctivitis. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 482-488.	1.1	115
47	Small Fiber Peripheral Neuropathy in Wilson Disease: An In Vivo Documentation by Corneal Confocal Microscopy. Investigative Ophthalmology and Visual Science, 2015, 56, 1390-1395.	3.3	32
48	Safety & Efficacy of Human Plasma Derived Plasminogen Ophthalmic Drops for Treatment of Ligneous Conjunctivitis: Report of Phase 2/3 Clinical Trial. Blood, 2015, 126, 2288-2288.	0.6	3
49	Atmospheric-Pressure Cold Plasma Induces Transcriptional Changes in Ex Vivo Human Corneas. PLoS ONE, 2015, 10, e0133173.	1.1	21
50	Allergic mediators in tears: what's new?. Acta Ophthalmologica, 2015, 93, n/a-n/a.	0.6	0
51	Identification of human tear fluid biomarkers in vernal keratoconjunctivitis using iTRAQ quantitative proteomics. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 254-260.	2.7	40
52	Vernal keratoconjunctivitis: A severe allergic eye disease with remodeling changes. Pediatric Allergy and Immunology, 2014, 25, 314-322.	1.1	93
53	Ocular Allergy. , 2014, , 1-18.		0
54	Allergy and allergic mediators in tears. Experimental Eye Research, 2013, 117, 106-117.	1.2	93

#	Article	IF	Citations
55	Management of Vernal Keratoconjunctivitis. Ophthalmology and Therapy, 2013, 2, 73-88.	1.0	77
56	Vernal Keratoconjunctivitis-like Disease in Adults. American Journal of Ophthalmology, 2013, 155, 796-803.	1.7	40
57	Is visual function affected in severe ocular allergies?. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 558-562.	1.1	14
58	Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1327-1337.	2.7	165
59	Corneal Confocal Microscopy in Patients with Vernal Keratoconjunctivitis. Ophthalmology, 2012, 119, 509-515.	2.5	58
60	Clinical results on the efficacy of Thealoz vs autologous serum in moderate to severe dry eye. Acta Ophthalmologica, 2012, 90, 0-0.	0.6	0
61	Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. Journal of Allergy and Clinical Immunology, 2011, 128, 896-897.e9.	1.5	43
62	Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1360-1366.	2.7	33
63	Transforming growth factor-Î²/Smad - signalling pathway and conjunctival remodelling in vernal keratoconjunctivitis. Clinical and Experimental Allergy, 2011, 41, 52-60.	1.4	29
64	The immunology of allergic ocular surface disease. Acta Ophthalmologica, 2011, 89, 0-0.	0.6	0
65	Immune modulation in ocular allergy: Update and future directions. Acta Ophthalmologica, 2011, 89, 0-0.	0.6	0
66	Mechanisms of corneal allergic reaction: new options for treatment. Expert Review of Ophthalmology, 2010, 5, 545-556.	0.3	3
67	Tailored Approach to the Treatment of Vernal Keratoconjunctivitis. Ophthalmology, 2010, 117, 1294-1299.	2.5	54
68	Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opinion on Pharmacotherapy, 2010, 11, 969-981.	0.9	23
69	Allergic Disease of the Conjunctiva and Cornea. Essentials in Ophthalmology, 2010, , 97-120.	0.0	1
70	Characterization of dendritic cell phenotype in allergic conjunctiva: increased expression of FcÉ›RI, the high-affinity receptor for immunoglobulin E. Eye, 2009, 23, 2099-2104.	1.1	17
71	Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 710-717.	2.7	98
72	Cytokine and chemokine levels in tears and in corneal fibroblast cultures before and after excimer laser treatment. Journal of Cataract and Refractive Surgery, 2009, 35, 240-247.	0.7	41

#	Article	IF	Citations
73	Prospective, Multicenter Demographic and Epidemiological Study on Vernal Keratoconjunctivitis: A Glimpse of Ocular Surface in Italian Population. Ophthalmic Epidemiology, 2009, 16, 38-41.	0.8	64
74	Allergy and the eye. Clinical and Experimental Immunology, 2008, 153, 17-21.	1.1	113
75	Urban eye allergy syndrome: a new clinical entity?. Current Medical Research and Opinion, 2008, 24, 2295-2302.	0.9	32
76	Prevalence of vernal keratoconjunctivitis: a rare disease?. British Journal of Ophthalmology, 2008, 92, 1097-1102.	2.1	93
77	Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. British Journal of Ophthalmology, 2007, 91, 1662-1666.	2.1	22
78	Trypsin Inhibitory Capacity in Vernal Keratoconjunctivitis. , 2007, 48, 264.		21
79	Allergic Conjunctivitis: Clinical Consequences and an Update on Understanding Its Pathophysiology. , 2007, , 25-43.		0
80	Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 429-435.	1.1	99
81	Antibody array characterization of inflammatory mediators in allergic and normal tears in the open and closed eye environments. Experimental Eye Research, 2007, 85, 528-538.	1.2	53
82	New drug treatments for ocular allergies. Expert Review of Ophthalmology, 2007, 2, 397-408.	0.3	1
83	Matrix metalloproteases in vernal keratoconjunctivitis, nasal polyps and allergic asthma. Clinical and Experimental Allergy, 2007, 37, 872-879.	1.4	18
84	Altered Expression of Neurotransmitter Receptors and Neuromediators in Vernal Keratoconjunctivitis. JAMA Ophthalmology, 2006, 124, 462.	2.6	62
85	In Vitro Effects of Fluoroquinolone and Aminoglycoside Antibiotics on Human Keratocytes. Cornea, 2006, 25, 85-90.	0.9	12
86	Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmologica, 2006, 84, 406-410.	0.4	133
87	Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clinical and Experimental Allergy, 2006, 36, 777-784.	1.4	189
88	Th1- and Th2-type cytokines in chronic ocular allergy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 1240-1245.	1.0	85
89	In-vivo diagnostic measurements of ocular inflammation. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 464-472.	1.1	38
90	Urokinase Plasminogen Activator, uPa Receptor, and Its Inhibitor in Vernal Keratoconjunctivitis. , 2005, 46, 1364.		25

#	Article	IF	Citations
91	Emerging drugs for ocular allergy. Expert Opinion on Emerging Drugs, 2005, 10, 505-520.	1.0	46
92	Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Current Medical Research and Opinion, 2004, 20, 1167-1173.	0.9	38
93	Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clinical Therapeutics, 2003, 25, 2539-2552.	1.1	59
94	Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology, 2003, 110, 487-492.	2.5	137
95	Effects of Th2 Cytokines on Expression of Collagen, MMP-1, and TIMP-1 in Conjunctival Fibroblasts. , 2003, 44, 183.		67
96	Vernal Keratoconjunctivitis. International Ophthalmology Clinics, 2003, 43, 41-58.	0.3	52
97	Tear Levels and Activity of Matrix Metalloproteinase (MMP)-1 and MMP-9 in Vernal Keratoconjunctivitis. , 2003, 44, 3052.		116
98	Tumor Necrosis Factor-Alpha (TNF-Î±) in Seasonal Allergic Conjunctivitis and Vernal Keratoconjunctivitis. European Journal of Ophthalmology, 2003, 13, 606-610.	0.7	39
99	The Anti-Allergic Effects of a Cromolyn Sodium-Chlorpheniramine Combination Compared to Ketotifen in the Conjunctival Allergen Challenge Model. European Journal of Ophthalmology, 2003, 13, 128-133.	0.7	6
100	Histamine-induced cytokine production and ICAM-1 expression in human conjunctival fibroblasts. Current Eye Research, 2002, 25, 189-196.	0.7	32
101	Efficacy and Safety of Desonide Phosphate for the Treatment of Allergic Conjunctivitis. Cornea, 2002, 21, 476-481.	0.9	18
102	Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clinical Therapeutics, 2002, 24, 409-416.	1.1	24
103	Vernal keratoconjunctivitis: pathogenesis and treatment. Progress in Retinal and Eye Research, 2002, 21, 319-339.	7.3	223
104	The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Current Allergy and Asthma Reports, 2002, 2, 325-331.	2.4	64
105	Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. American Journal of Ophthalmology, 2001, 131, 691-698.	1.7	34
106	Effects of Cyclosporin A on Human Conjunctival Fibroblasts. JAMA Ophthalmology, 2001, 119, 1512.	2.6	48
107	Role of Histamine in Allergic Conjunctivitis. Acta Ophthalmologica, 2000, 78, 18-21.	0.4	48
108	Safety and Efficacy Comparison of Emedastine 0.05% Ophthalmic Solution Compared to Levocabastine 0.05% Ophthalmic Suspension in Pediatric Subjects with Allergic Conjunctivitis. Acta Ophthalmologica, 2000, 78, 42-47.	0.4	20

#	Article	IF	Citations
109	An Efficacy and Tolerance Comparison of Emedastine Difumarate 0.05% and Levocabastine Hydrochloride 0.05%: Reducing Chemosis and Eyelid Swelling in Subjects with Seasonal Allergic Conjunctivitis. Acta Ophthalmologica, 2000, 78, 48-51.	0.4	19
110	Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model. British Journal of Ophthalmology, 2000, 84, 1228-1232.	2.1	42
111	Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. American Journal of Ophthalmology, 2000, 129, 151-158.	1.7	103
112	Growth factors and collagen distribution in vernal keratoconjunctivitis. Investigative Ophthalmology and Visual Science, 2000, 41, 4175-81.	3.3	43
113	Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clinical and Experimental Allergy, 1999, 29, 1214-1222.	1.4	113
114	Histamine Effects on Conjunctival Fibroblasts from Patients with Vernal Conjunctivitis. Experimental Eye Research, 1999, 68, 739-746.	1.2	66
115	Pathophysiology of Allergic Conjunctivitis. Acta Ophthalmologica, 1999, 77, 21-23.	0.4	29
116	Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Investigative Ophthalmology and Visual Science, 1999, 40, 3036-40.	3.3	80
117	Procollagens and Inflammatory Cytokine Concentrations in Tarsal and Limbal Vernal Keratoconjunctivitis. Experimental Eye Research, 1998, 67, 105-112.	1.2	80
118	Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. British Journal of Ophthalmology, 1997, 81, 23-26.	2.1	56
119	Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 1995, 50, 610-613.	2.7	93
120	Collagen types I and III in giant papillae of vernal keratoconjunctivitis.. British Journal of Ophthalmology, 1995, 79, 482-485.	2.1	39
121	The role of eosinophil cationic protein (ECP) and histamine in vernal keratoconjunctivitis. Ocular Immunology and Inflammation, 1995, 3, 23-28.	1.0	12
122	Antigen sensitivity evaluated by tear-specific and serum-specific IgE, skin tests, and conjunctival and nasal provocation tests in patients with ocular allergic disease. Eye, 1993, 7, 461-464.	1.1	64
123	Topical Use of Cyclosporine in the Treatment of Vernal Keratoconjunctivitis. American Journal of Ophthalmology, 1990, 110, 641-645.	1.7	150
124	Correlation between conjunctival provocation test (CPT) and systemic allergometric tests in allergic conjunctivitis. Eye, 1990, 4, 760-764.	1.1	41